GH Research PLC (NASDAQ:GHRS) Receives $30.86 Consensus PT from Analysts

GH Research PLC (NASDAQ:GHRS) has earned an average rating of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $30.86.

GHRS has been the subject of several recent research reports. Stifel Nicolaus upped their target price on GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, February 27th. Cantor Fitzgerald assumed coverage on GH Research in a research report on Thursday, February 13th. They issued an “overweight” rating and a $14.00 target price on the stock. Royal Bank of Canada began coverage on shares of GH Research in a report on Friday, March 7th. They set an “outperform” rating and a $31.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of GH Research in a report on Monday, January 27th. Finally, Guggenheim assumed coverage on shares of GH Research in a research note on Thursday, March 13th. They set a “buy” rating and a $32.00 target price for the company.

Hedge Funds Weigh In On GH Research

A number of institutional investors and hedge funds have recently bought and sold shares of GHRS. RA Capital Management L.P. raised its position in shares of GH Research by 1.3% during the 3rd quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company’s stock worth $44,734,000 after buying an additional 85,000 shares in the last quarter. Geode Capital Management LLC raised its holdings in GH Research by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 72,513 shares of the company’s stock worth $508,000 after purchasing an additional 3,092 shares in the last quarter. Diadema Partners LP acquired a new stake in GH Research in the fourth quarter worth approximately $711,000. Lynx1 Capital Management LP boosted its stake in GH Research by 15.8% during the 4th quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock valued at $34,013,000 after purchasing an additional 663,100 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of GH Research by 26.8% during the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock valued at $286,000 after purchasing an additional 8,641 shares during the period. Institutional investors own 56.90% of the company’s stock.

GH Research Trading Down 7.6 %

GH Research stock opened at $9.32 on Tuesday. The stock has a 50 day moving average of $11.93 and a 200-day moving average of $9.44. The stock has a market cap of $484.90 million, a P/E ratio of -11.80 and a beta of 0.84. GH Research has a 52 week low of $6.00 and a 52 week high of $20.50.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. As a group, equities analysts predict that GH Research will post -0.8 earnings per share for the current fiscal year.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).